State VA
Clinical Trials in Virginia
Recruiting clinical trials with at least one study location in Virginia. Data updated daily from ClinicalTrials.gov.
Top Conditions in Virginia
NCT06136650 Phase 3
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Age...
Condition
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment
1,314 pts
Location
United States, Australia, Brazil
Sponsor
Merck Sharp & Dohme LLC
NCT05580562 Phase 3
Recruiting
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study...
Condition
H3 K27M
Enrollment
450 pts
Location
United States, Argentina, Australia
Sponsor
Jazz Pharmaceuticals
NCT06395519 Phase 1, Phase 2
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Condition
Advanced or Metastatic Solid Tumors
Enrollment
120 pts
Location
United States
Sponsor
858 Therapeutics, Inc.
NCT05966194 Phase 2
Recruiting
RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radia...
Condition
Oral Mucositis
Enrollment
216 pts
Location
United States
Sponsor
EpicentRx, Inc.
NCT03981575 N/A
Recruiting
Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Condition
Myotonic Dystrophy 1
Enrollment
700 pts
Location
United States, Canada, Germany
Sponsor
Virginia Commonwealth Universi
NCT07174583 Phase 1, Phase 2
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell L...
Condition
Small-cell Lung Cancer
Enrollment
208 pts
Location
United States, Australia, Brazil
Sponsor
IDEAYA Biosciences
NCT05855200 Phase 3
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage ...
Condition
Colonic Neoplasms
Enrollment
892 pts
Location
United States, Argentina, Australia
Sponsor
GlaxoSmithKline
NCT06023186 N/A
Recruiting
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
Condition
Obstructive Hypertrophic Cardiomyopathy
Enrollment
20 pts
Location
United States
Sponsor
Michael Ayers
NCT05230173 N/A
Recruiting
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remi...
Condition
Ulcerative Colitis
Enrollment
250 pts
Location
United States
Sponsor
University of California, San
NCT06662786 Phase 3
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or ...
Condition
Colorectal Neoplasms
Enrollment
1,000 pts
Location
United States, Belgium, Brazil
Sponsor
Janssen Research & Development
NCT06874595 N/A
Recruiting
Psychobiological Responses Following Exercise and Brain Stimulation
Condition
Psychological
Enrollment
29 pts
Location
United States
Sponsor
Virginia Commonwealth Universi
NCT05156983 Phase 3
Recruiting
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Nee...
Condition
Coagulation Disorder
Enrollment
328 pts
Location
United States, Argentina, Austria
Sponsor
Takeda
NCT03547973 Phase 2
Recruiting
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Canno...
Condition
Metastatic Urothelial Cancer
Enrollment
827 pts
Location
United States, France, Germany
Sponsor
Gilead Sciences
NCT04989803 Phase 1, Phase 2
Recruiting
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-...
Condition
Relapsed and/or Refractory B-cell Lymphoma
Enrollment
247 pts
Location
United States, Australia, Germany
Sponsor
Kite, A Gilead Company
NCT07065903 N/A
Recruiting
Nimodipine Variability in SAH
Condition
Subarachnoid Aneurysm Hemorrhage
Enrollment
500 pts
Location
United States, Canada
Sponsor
University of Alberta
NCT01804686 Phase 3
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Condition
Chronic Lymphocytic Leukemia
Enrollment
700 pts
Location
United States, Argentina, Australia
Sponsor
Janssen Research & Development
NCT06465810 N/A
Recruiting
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Condition
Transthyretin Amyloidosis
Enrollment
1,850 pts
Location
United States, Canada, China
Sponsor
AstraZeneca
NCT06422923 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral...
Condition
Epilepsy, Temporal Lobe
Enrollment
10 pts
Location
United States
Sponsor
Neurona Therapeutics
NCT03161223 Phase 1, Phase 2
Recruiting
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Az...
Condition
Lymphoma, T-Cell
Enrollment
148 pts
Location
United States
Sponsor
University of Virginia
NCT04293562 Phase 3
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilterit...
Condition
Acute Myeloid Leukemia
Enrollment
1,186 pts
Location
United States, Australia, Canada
Sponsor
Children's Oncology Group
NCT06892379 Phase 1
Recruiting
A Study of HS-20110 in Participants With Advanced Solid Tumors
Condition
Solid Tumors
Enrollment
475 pts
Location
United States, China
Sponsor
Hansoh BioMedical R&D Company
NCT04305769 Phase 2
Recruiting
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
Condition
Clostridioides Difficile Infection
Enrollment
260 pts
Location
United States
Sponsor
University of Virginia
NCT07089888 Phase 3
Recruiting
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Condition
Tophaceous Gout
Enrollment
250 pts
Location
United States
Sponsor
Crystalys Therapeutics
NCT06275360 Phase 2
Recruiting
Repositioning Immunotherapy in VetArans With Lung Cancer
Condition
Non-Small Cell Lung Cancer
Enrollment
25 pts
Location
United States
Sponsor
VA Office of Research and Deve
NCT06703073 Phase 2
Recruiting
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
Condition
Acute Respiratory Distress Syndrome (ARDS)
Enrollment
600 pts
Location
United States
Sponsor
PPD Development, LP